Scarica l'app Stockscreener
62.23
0.95%
-0.60
Dopo l'orario di chiusura:
63.08
0.85
+1.37%
Exelixis Inc Borsa (EXEL) Ultime notizie
2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Zacks Investment Research
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace
Exelixis to release Q3FY26 results on Oct 29, 2026 - scanx.trade
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance Singapore
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView
Exelixis Inc stock hits all-time high at 61.21 USD - Investing.com
Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa
Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill
Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus
Exelixis (NasdaqGS:EXEL) Stock Price - Simply Wall Street
Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com
RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance
EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus
Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance
Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance
Is Exelixis Stock Engineered To Make You Money? - Yahoo Finance
Is Exelixis Stock Engineered To Make You Money? - Trefis
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Owning the Improvement Is Not Freedom to Operate: Exelixis v. MSN Shows the Reach of Earlier Genus Patents - The National Law Review
Owning the Improvement Is Not Freedom to Operate: Exelixis v. MSN Shows the Reach of Earlier Genus Patents - The National Law Review
Exelixis delays cancer-drug review: what it means for Exelixis stock - AD HOC NEWS
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup - ChartMill
Exelixis, Inc. - Simply Wall Street
Exelixis, Inc. Podcast | EXEL Podcasts & Related Content - finance.biggo.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis Shares Rising on CABOMETYX Revenue - Yahoo Finance
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com Nigeria
Exelixis stock hits all-time high at 59.73 USD - Investing.com
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com South Africa
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Exelixis, Inc. (EXEL) Stock forecasts - au.finance.yahoo.com
Cash flow from operating activities of Exelixis, Inc. – HAN:EX9 - TradingView
Return on equity % of Exelixis, Inc. – HAN:EX9 - TradingView
Exelixis (NasdaqGS:EXEL) Stock Forecast & Analyst Predictions - Simply Wall Street
Exelixis, Inc. (EXEL) Stock forecasts - sg.finance.yahoo.com
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? - TradingView
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - easternprogress.com
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo! Finance Canada
0.60%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):